Consumer telehealth · Weight-care / GLP-1
Eden
Eden is a consumer telehealth brand for medical weight loss and related wellness programs, connecting adults to clinicians and pharmacy fulfillment for GLP-1 care. It is not a hospital system.
Strong fit
- Adults comparing cash-pay compounded GLP-1 telehealth programs with clear monthly pricing
- Patients who want clinician review plus pharmacy fulfillment in one consumer weight-care path
- Buyers evaluating mid-market DTC weight peers rather than employer metabolic programs
Weak fit
- Patients who need insurance-billed obesity medicine with in-network coaching bundles
- People seeking only brand-name Wegovy or Zepbound with no compounded option discussion
- Buyers shopping a clinic EHR or practice-staffing vendor with no consumer telehealth need
Bottom line
Eden earns a Recommend on our consumer weight-care board. The Colorado telehealth brand (tryeden.com) connects adults to independent clinicians for GLP-1 weight programs and, as of 2025, operates an owned 503A pharmacy after acquiring Contigo Compounding. Public pricing for compounded semaglutide and tirzepatide is easier to compare than coaching-plus-drug membership models. Outcomes depend on clinician judgment, adherence, and pharmacy fulfillment quality. Headcount near 80 and membership claims above 100,000 put it in the prefer mid-market class without household-giant scale. Score sits just under Found and above Fridays and GobyMeds on this weight-care board.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Eden (tryeden.com) is a Greenwood Village, Colorado consumer telehealth company founded in 2023 by Adam McBride, Josh Khan, and Daniel Dietz. It focuses on medical weight loss and related wellness programs with clinician review and pharmacy fulfillment.
It is a DTC weight-care product vendor, not a hospital system. Compare Found when metabolic coaching plus medication is the buy, Fridays when longevity add-ons matter, and GobyMeds when published low cash-pay GLP-1 bundles are the priority.
Score reflects program access and pricing clarity, with pharmacy ownership as a differentiator that still needs label-level verification on every fill.
Competitor landscape
| Vendor | Overall | Ease of use |
|---|---|---|
| Found | 7.4 | 7.2 |
| Eden | 7.3 | 7.2 |
| Fridays | 7.1 | 7.0 |
| Mochi Health | 7.0 | 6.6 |
| Nu Image Medical | 6.8 | 6.5 |
| Henry Meds | 6.7 | 6.3 |
| GobyMeds | 6.6 | 6.5 |
Pricing
| Item | Detail |
|---|---|
| Model | Cash-pay telehealth membership or medication bundles for compounded and brand GLP-1 options; public monthly prices appear on marketing and affiliate pages. |
| What usually drives cost | Medication type (semaglutide vs tirzepatide), dose, prepaid term, and whether brand-name drugs are prescribed. |
| What to ask in diligence | All-in monthly cost including clinician access, medication, and shipping at your expected dose. |
| Published pricing | Public list price: compounded plans often advertised near low-to-mid hundreds per month depending on drug and term; confirm current checkout pricing. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Eden to function | |
| Honest eligibility and medication history ready for clinician review | Incomplete intake delays or blocks prescribing. |
| Clear budget for cash-pay medication and visits | Surprise totals drive abandonment. |
| Plan for injection training or oral alternatives if offered | Unprepared patients stall after ship. |
| Shipping address and cold-chain expectations confirmed | Failed delivery wastes medication. |
| Follow-up cadence the patient will actually keep | One-time fills without check-ins weaken results. |
| What will maximize your value | |
| Complete labs or required screening before dose escalation | Skipping gates raises safety risk. |
| Track weight, side effects, and adherence weekly for 90 days | App opens are not outcomes. |
| Use one pharmacy path; avoid duplicate telehealth scripts | Split sourcing confuses dosing. |
| Message the care team early on nausea or supply gaps | Silent side effects cause drop-off. |
| Re-price the plan at each refill before autopay | Dose changes alter monthly cost. |
| Deal-breakers | |
| You need insurance-only obesity care and refuse cash-pay models. | |
| A clinician determines GLP-1 therapy is inappropriate. | |
| You cannot receive or store refrigerated medication safely. | |
| You will not complete required follow-up or screening. | |
| You expect a hospital procedure pathway from a DTC telehealth brand. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Intake | 1-7 days - Quiz, history, eligibility. |
| 2 | Clinician review | 1-7 days - Approval or alternatives. |
| 3 | First shipment | 2-10 days - Pharmacy fill and delivery. |
| 4 | Titration & follow-up | 1-6 months - Dose changes and check-ins. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.